NursingNotes
  • News
  • Clinical Care
  • Education
    • Student Nurses
    • Student Midwives
    • Nursing Associates
  • Resources
  • Opinion
No Result
View All Result
NursingNotes
No Result
View All Result
Home News Clinical

Pancreatic cancer patients to have routine access to life extending drug after new deal

by NursingNotes
4th August 2017
Share on FacebookShare on Twitter

Related Posts

Tesla electric car ‘drives’ children to theatre

Study exposes link between delayed observations and 12-hour shifts

NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and provided more evidence on its effectiveness.

Nab-paclitaxel, also known as Abraxane, made by Celgene will be routinely available as an option for patients with pancreatic cancer that has progressed.

When Abraxane is added to a standard chemotherapy, called gemcibatine the evidence has found it extends life by an average of 2.4 months.

If other combination chemotherapy treatments are unsuitable for a patient, NICE recommends offering Abraxane instead of this standard chemotherapy on its own.

It works by blocking the action of the proteins within cancer cells that cause them to grow and divide.

NICE has reviewed its guidance from 2015 which did not recommend Abraxane for routine NHS use for not being cost-effective.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: “The life expectancy of pancreatic cancer is poor, with patients usually living for only up to 6 months. It’s incredibly important that patients and families affected by this disease are able to have routine access to this life extending treatment.”

There are almost 10,000 new cases of pancreatic cancer each year in the UK, and less than 1% survive for 10 or more years.

This is a final appraisal determination for Abraxane. The company, healthcare professionals and patient/carer organisations now have until Friday 1 September to appeal the decision.

theHandover

The latest healthcare news and updates direct to your email inbox. We do not sell or share your information. 

Thank you!

You have successfully joined our subscriber list.

Related Posts

HEY

Tesla electric car ‘drives’ children to theatre

18th February 2019
Adobe

Study exposes link between delayed observations and 12-hour shifts

14th February 2019

Two-hourly repositioning is ‘unintentional institutional abuse,’ claims study

Scrapping the 4-hour target would lead to “endless hours of waiting in A&E departments”

Social media to blame for vaccine ‘misinformation’

Hospital trust develops ‘WhatsApp-style’ flu alert

School children to be taught CPR and basic first aid

Patients at risk of harm from ‘inappropriate placement’ of sats probes

Unidentified patients should be given ‘randomly generated names’

Pregabalin and gabapentin will become controlled drugs in April

Adobe

Patients urged to complain in order to ‘improve standards of care’

19th February 2019
HEY

Tesla electric car ‘drives’ children to theatre

18th February 2019
Adobe

Fifteen health and care professions to see a ‘disproportionate hike in registration fees’

14th February 2019
Adobe

Study exposes link between delayed observations and 12-hour shifts

14th February 2019
NHS England

Nurse tells NHS chiefs ‘I have never seen the NHS in such a bad state’

13th February 2019
Adobe

NHS workers urged not to ditch ‘excellent’ pension scheme

13th February 2019
  • Agenda for Change
  • Terms of Service
  • Privacy Policy
  • Contact us
  • Sitemap

© 2018 indeMedia.

No Result
View All Result

© 2018 indeMedia.